Your browser is no longer supported. Please, upgrade your browser.
ETNB 89bio, Inc. daily Stock Chart
89bio, Inc.
Index- P/E- EPS (ttm)-4.57 Insider Own- Shs Outstand13.80M Perf Week5.87%
Market Cap499.55M Forward P/E- EPS next Y-4.00 Insider Trans- Shs Float6.44M Perf Month-1.18%
Income-60.30M PEG- EPS next Q-0.86 Inst Own69.70% Short Float7.74% Perf Quarter-27.58%
Sales- P/S- EPS this Y-210.60% Inst Trans-3.10% Short Ratio3.32 Perf Half Y6.23%
Book/sh5.06 P/B4.99 EPS next Y-27.80% ROA-86.70% Target Price- Perf Year-
Cash/sh3.73 P/C6.76 EPS next 5Y16.00% ROE-130.00% 52W Range14.00 - 47.25 Perf YTD-4.03%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.61% Beta-
Dividend %- Quick Ratio11.10 Sales past 5Y- Gross Margin- 52W Low80.21% ATR2.10
Employees24 Current Ratio11.10 Sales Q/Q- Oper. Margin- RSI (14)45.07 Volatility4.83% 6.09%
OptionableNo Debt/Eq0.00 EPS Q/Q47.00% Profit Margin- Rel Volume3.08 Prev Close23.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume150.18K Price25.23
Recom1.40 SMA202.47% SMA50-16.40% SMA200-10.55% Volume462,725 Change6.32%
Oct-19-20Initiated Raymond James Strong Buy $65
Sep-25-20Upgrade BofA Securities Neutral → Buy $37 → $43
Jul-31-20Initiated Piper Sandler Overweight $54
Jul-23-20Initiated BTIG Research Buy
Jul-07-20Initiated Chardan Capital Markets Buy $58
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
Sep-28-20 05:18PM  
Sep-23-20 07:00AM  
Sep-16-20 08:51PM  
Sep-14-20 05:21PM  
Sep-13-20 07:53PM  
Sep-03-20 08:30AM  
Aug-13-20 04:05PM  
Aug-11-20 08:32AM  
Aug-10-20 12:15PM  
Aug-03-20 04:05PM  
Jul-24-20 06:12PM  
Jul-13-20 10:18AM  
Jul-10-20 08:26AM  
Jul-07-20 09:30PM  
Jul-06-20 06:30AM  
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLCDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:09 PM
Naschitz AnatDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorSep 17Buy28.001,300,00036,400,0004,736,214Sep 21 04:30 PM
Longitude Capital Partners III10% OwnerJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:11 PM
Grunberg GregoryDirectorJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:08 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 08Buy27.50275,0007,562,5003,436,214Jul 10 04:32 PM